Radiotherapy & Oncology
Volume 96, Issue 2 , Pages 145-152 , August 2010

The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: Exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer

  • Philippe Lambin

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology (MAASTRO Clinic), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, Dr. Tanslaan 12, NL-6229 ET Maastricht, The Netherlands.
    • These authors contributed equally to this work.
    • ,
  • Steven F. Petit

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • These authors contributed equally to this work.
    • ,
  • Hugo J.W.L. Aerts

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • ,
  • Wouter J.C. van Elmpt

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • ,
  • Cary J.G. Oberije

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • ,
  • Maud H.W. Starmans

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • ,
  • Ruud G.P.M. van Stiphout

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • ,
  • Guus A.M.S. van Dongen

      Affiliations

    • Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, The Netherlands
    • ,
  • Kristoff Muylle

      Affiliations

    • Department of Nuclear Medicine, Institut Jules Bordet, Université Libre De Bruxelles (ULB), Brussels, Belgium
    • ,
  • Patrick Flamen

      Affiliations

    • Department of Nuclear Medicine, Institut Jules Bordet, Université Libre De Bruxelles (ULB), Brussels, Belgium
    • ,
  • André L.A.J. Dekker

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands
    • ,
  • Dirk De Ruysscher

      Affiliations

    • Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands

Received 23 March 2010 ,Revised 7 July 2010 ,Accepted 7 July 2010.

References 

  1. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol. 2009;4:1
  2. Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004;60:1241–1256
  3. van Baardwijk A, Bosmans G, Bentzen SM, et al. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. Int J Radiat Oncol Biol Phys. 2008;71:1103–1110
  4. van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol. 2010;28:1380–1386
  5. Chun FK, Karakiewicz PI, Briganti A, et al. Prostate cancer nomograms: an update. Eur Urol. 2006;50:914–926[discussion 926]
  6. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys. 2008;71:1065–1073
  7. Bradley JD, Hope A, El Naqa I, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys. 2007;69:985–992
  8. Dehing-Oberije C, Yu S, De Ruysscher D, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:355–362
  9. Smith WP, Doctor J, Meyer J, Kalet IJ, Phillips MH. A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model. Artif Intell Med. 2009;46:119–130
  10. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24:31–37
  11. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  12. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–117
  13. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861–872
  14. Alonzi R, Hoskin P. Functional imaging in clinical oncology: magnetic resonance imaging- and computerised tomography-based techniques. Clin Oncol (R Coll Radiol). 2006;18:555–570
  15. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392
  16. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  17. Malinen E, Sovik A, Hristov D, Bruland OS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol. 2006;51:4903–4921
  18. Sovik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol. 2007;52:499–513
  19. Alber M, Paulsen F, Eschmann SM, Machulla HJ. On biologically conformal boost dose optimization. Phys Med Biol. 2003;48:N31–N35
  20. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68:291–300
  21. Yang Y, Xing L. Towards biologically conformal radiation therapy (BCRT): selective IMRT dose escalation under the guidance of spatial biology distribution. Med Phys. 2005;32:1473–1484
  22. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  23. Petit SF, Aerts HJ, van Loon JG, et al. Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother Oncol. 2009;91:393–398
  24. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–6465
  25. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  26. Magagnin MG, Koritzinsky M, Wouters BG. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist Updat. 2006;9:185–197
  27. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiotherapy. Radiat Res. 1997;147:541–550
  28. Petit SF, Dekker AL, Seigneuric R, et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol. 2009;54:2179–2196
  29. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987;111:292–304
  30. Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol. 2002;41:304–312
  31. Rajendran JG, Schwartz DL, O’Sullivan J, et al. Tumor hypoxia imaging with [F-18]fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–5441
  32. Zimny M, Gagel B, Dimartino E, et al. FDG-a marker of tumour hypoxia? A comparison with [(18)F]fluoromisonidazole and pO (2)-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 2006;33:1426–1431
  33. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–260
  34. Laprie A, Catalaa I, Cassol E, et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2008;70:773–781
  35. Abramyuk A, Tokalov S, Zophel K, et al. Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?. Radiother Oncol. 2009;91:399–404
  36. Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys. 2008;71:1402–1407
  37. Schutze C, Bergmann R, Yaromina A, et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. Radiother Oncol. 2007;83:311–315
  38. van Baardwijk A, Bosmans G, van Suylen RJ, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol. 2008;87:55–58
  39. Gillham C, Zips D, Ponisch F, et al. Additional PET/CT in week 5–6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol. 2008;88:335–341
  40. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123–131
  41. Muylle K, Vugts DJ, Meuleman N, et al. Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma: comparison with 18FDG-PET. Eur J Nucl Med Mol Imaging. 2009;36:OP424;[abstract]
  42. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:541–551
  43. Chen GP, Ahunbay E, Schultz C, Li XA. Development of an inverse optimization package to plan nonuniform dose distributions based on spatially inhomogeneous radiosensitivity extracted from biological images. Med Phys. 2007;34:1198–1205
  44. Rodrigues G, Lock M, D’Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer – a systematic review. Radiother Oncol. 2004;71:127–138
  45. van Beek EJ, Hoffman EA. Functional imaging: CT and MRI. Clin Chest Med. 2008;29:195–216vii
  46. Eichinger M, Tetzlaff R, Puderbach M, Woodhouse N, Kauczor HU. Proton magnetic resonance imaging for assessment of lung function and respiratory dynamics. Eur J Radiol. 2007;64:329–334
  47. Ireland RH, Bragg CM, McJury M, et al. Feasibility of image registration and intensity-modulated radiotherapy planning with hyperpolarized helium-3 magnetic resonance imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:273–281
  48. Simon BA. Non-invasive imaging of regional lung function using X-ray computed tomography. J Clin Monit Comput. 2000;16:433–442
  49. Guerrero T, Sanders K, Castillo E, et al. Dynamic ventilation imaging from four-dimensional computed tomography. Phys Med Biol. 2006;51:777–791
  50. Guerrero T, Sanders K, Noyola-Martinez J, et al. Quantification of regional ventilation from treatment planning CT. Int J Radiat Oncol Biol Phys. 2005;62:630–634
  51. Yaremko BP, Guerrero TM, Noyola-Martinez J, et al. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys. 2007;68:562–571
  52. Seppenwoolde Y, Muller SH, Theuws JC, et al. Radiation dose-effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47:681–690
  53. Marks LB, Spencer DP, Bentel GC, et al. The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys. 1993;26:659–668
  54. Lavrenkov K, Christian JA, Partridge M, et al. A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. Radiother Oncol. 2007;83:156–162
  55. Seppenwoolde Y, Engelsman M, De Jaeger K, et al. Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol. 2002;63:165–177
  56. McGuire SM, Marks LB, Yin FF, Das SK. A methodology for selecting the beam arrangement to reduce the intensity-modulated radiation therapy (IMRT) dose to the SPECT-defined functioning lung. Phys Med Biol. 2010;55:403–416
  57. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293–321
  58. Hart JP, McCurdy MR, Ezhil M, et al. Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. Int J Radiat Oncol Biol Phys. 2008;71:967–971
  59. De Ruysscher D, Houben A, Aerts HJ, et al. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study. Radiother Oncol. 2009;91:415–420
  60. Petit S, Elmpt v, Dehing-Oberije. 18F-fluorodeoxyglucose uptake patterns in the lung before radiotherapy identify areas that are more susceptible to radiation-induced lung toxicity in non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys 2010; doi:10.1016/j.jirobp.2010.06.016.
  61. Sovik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2007;68:1496–1504
  62. Vanderstraeten B, Duthoy W, De Gersem W, De Neve W, Thierens H. [18F]Fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol. 2006;79:249–258
  63. Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys. 2009;73:650–658
  64. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;91:85–94
  65. Shioyama Y, Jang SY, Liu HH, et al. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;68:1349–1358
  66. Das S. A role for biological optimization within the current treatment planning paradigm. Med Phys. 2009;36:4672–4682
  67. Das SK, Miften MM, Zhou S, et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys. 2004;31:1452–1461
  68. Heath E, Unkelbach J, Oelfke U. Incorporating uncertainties in respiratory motion into 4D treatment plan optimization. Med Phys. 2009;36:3059–3071
  69. Witte MG, van der Geer J, Schneider C, Lebesque JV, Alber M, van Herk M. IMRT optimization including random and systematic geometric errors based on the expectation of TCP and NTCP. Med Phys. 2007;34:3544–3555
  70. van Elmpt W, McDermott L, Nijsten S, Wendling M, Lambin P, Mijnheer B. A literature review of electronic portal imaging for radiotherapy dosimetry. Radiother Oncol. 2008;88:289–309
  71. Nijsten SM, van Elmpt WJ, Mijnheer BJ, et al. Prediction of DVH parameter changes due to setup errors for breast cancer treatment based on 2D portal dosimetry. Med Phys. 2009;36:83–94
  72. McDermott LN, Wendling M, Sonke JJ, van Herk M, Mijnheer BJ. Replacing pretreatment verification with in vivo EPID dosimetry for prostate IMRT. Int J Radiat Oncol Biol Phys. 2007;67:1568–1577
  73. Renner WD. 3D dose reconstruction to insure correct external beam treatment of patients. Med Dosim. 2007;32:157–165
  74. Van Esch A, Depuydt T, Huyskens DP. The use of an aSi-based EPID for routine absolute dosimetric pre-treatment verification of dynamic IMRT fields. Radiother Oncol. 2004;71:223–234
  75. Wendling M, McDermott LN, Mans A, Sonke JJ, van Herk M, Mijnheer BJ. A simple backprojection algorithm for 3D in vivo EPID dosimetry of IMRT treatments. Med Phys. 2009;36:3310–3321
  76. Petit SF, van Elmpt WJ, Lambin P, Dekker AL. Dose recalculation in megavoltage cone-beam CT for treatment evaluation: removal of cupping and truncation artefacts in scans of the thorax and abdomen. Radiother Oncol. 2010;94:359–366
  77. van Elmpt W, Petit S, De Ruysscher D, Lambin P, Dekker A. 3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer. Radiother Oncol. 2010;94:188–194
  78. Chen J, Morin O, Aubin M, Bucci MK, Chuang CF, Pouliot J. Dose-guided radiation therapy with megavoltage cone-beam CT. Br J Radiol. 2006;79 Spec. No. 1:S87–S98
  79. Partridge M, Ebert M, Hesse BM. IMRT verification by three-dimensional dose reconstruction from portal beam measurements. Med Phys. 2002;29:1847–1858
  80. McDermott LN, Wendling M, Nijkamp J, et al. 3D in vivo dose verification of entire hypo-fractionated IMRT treatments using an EPID and cone-beam CT. Radiother Oncol. 2008;86:35–42
  81. van Zijtveld M, Dirkx M, Heijmen B. Correction of conebeam CT values using a planning CT for derivation of the “dose of the day”. Radiother Oncol. 2007;85:195–200
  82. van Elmpt W, Nijsten S, Petit S, Mijnheer B, Lambin P, Dekker A. 3D in vivo dosimetry using megavoltage cone-beam CT and EPID dosimetry. Int J Radiat Oncol Biol Phys. 2009;73:1580–1587
  83. Bosmans G, van Baardwijk A, Dekker A, et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2006;66:748–753
  84. Sonke JJ, Lebesque J, van Herk M. Variability of four-dimensional computed tomography patient models. Int J Radiat Oncol Biol Phys. 2008;70:590–598
  85. van Elmpt W, Öllers M, van Herwijnen H, et al. Volume or position changes of the primary lung tumor during (chemo-)radiotherapy cannot be used as a surrogate for the mediastinal lymph node changes: the case for optimal mediastinal lymph node imaging during radiotherapy. Int J Radiat Oncol Biol Phys; doi:10.1016/j.ijrobp.2009.10.059.
  86. Verellen D, De Ridder M, Storme G. A (short) history of image-guided radiotherapy. Radiother Oncol. 2008;86:4–13
  87. Woodford C, Yartsev S, Dar AR, Bauman G, Van Dyk J. Adaptive radiotherapy planning on decreasing gross tumor volumes as seen on megavoltage computed tomography images. Int J Radiat Oncol Biol Phys. 2007;69:1316–1322
  88. Harsolia A, Hugo GD, Kestin LL, Grills IS, Yan D. Dosimetric advantages of four-dimensional adaptive image-guided radiotherapy for lung tumors using online cone-beam computed tomography. Int J Radiat Oncol Biol Phys. 2008;70:582–589
  89. Ahunbay EE, Peng C, Chen GP, et al. An on-line replanning scheme for interfractional variations. Med Phys. 2008;35:3607–3615

☆ Data presented during the Breur Lecture in Berlin (ECCO meeting 2009).

PII: S0167-8140(10)00384-1

doi: 10.1016/j.radonc.2010.07.001

Radiotherapy & Oncology
Volume 96, Issue 2 , Pages 145-152 , August 2010

Article Tools

* Image Usage & Resolution